- Home
- IBRX vs PRDO Comparison
IBRX vs PRDO Comparison
Compare IBRX & PRDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- PRDO
- Stock Information
- Founded
- IBRX 2014
- PRDO 1994
- Country
- IBRX United States
- PRDO United States
- Employees
- IBRX N/A
- PRDO N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- PRDO Other Consumer Services
- Sector
- IBRX Health Care
- PRDO Real Estate
- Exchange
- IBRX Nasdaq
- PRDO Nasdaq
- Market Cap
- IBRX 1.9B
- PRDO 1.8B
- IPO Year
- IBRX N/A
- PRDO N/A
- Fundamental
- Price
- IBRX $2.94
- PRDO $27.67
- Analyst Decision
- IBRX Strong Buy
- PRDO Buy
- Analyst Count
- IBRX 3
- PRDO 1
- Target Price
- IBRX $13.58
- PRDO $32.00
- AVG Volume (30 Days)
- IBRX 6.3M
- PRDO 461.9K
- Earning Date
- IBRX 11-12-2024
- PRDO 02-19-2025
- Dividend Yield
- IBRX N/A
- PRDO 1.74%
- EPS Growth
- IBRX N/A
- PRDO N/A
- EPS
- IBRX N/A
- PRDO 1.99
- Revenue
- IBRX $7,332,000.00
- PRDO $652,751,000.00
- Revenue This Year
- IBRX $2,515.60
- PRDO N/A
- Revenue Next Year
- IBRX $766.19
- PRDO $2.27
- P/E Ratio
- IBRX N/A
- PRDO $13.93
- Revenue Growth
- IBRX 1218.71
- PRDO N/A
- 52 Week Low
- IBRX $2.28
- PRDO $16.12
- 52 Week High
- IBRX $10.53
- PRDO $29.47
- Technical
- Relative Strength Index (RSI)
- IBRX 48.30
- PRDO 61.97
- Support Level
- IBRX $2.28
- PRDO $25.48
- Resistance Level
- IBRX $2.54
- PRDO $26.63
- Average True Range (ATR)
- IBRX 0.25
- PRDO 0.63
- MACD
- IBRX 0.10
- PRDO 0.13
- Stochastic Oscillator
- IBRX 64.71
- PRDO 96.48
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About PRDO Perdoceo Education Corporation
Perdoceo Education Corp is an American for-profit education company that focuses on quality postsecondary education online to a diverse student population, along with campus-based and blended learning programs. The company's important segment include the American InterContinental University, and Colorado Technical University. These universities provide undergraduate, graduate, and doctoral degree programs focusing on business, technology, management, and social services with majority of the students enrolled in programs offered fully online. The majority of the company's revenue comes from the Colorado Technical University segment.